Return to homepagePandemic Pact

Differences in Prognosis between hypertensive patients using ACEI and BRAS and using other classes of antihypertensive drugs infected with SARS-cov-2

  • Funded by Decanato de Pesquisa e Inovação - Universidade de Brasilia (DPI)
  • Total publications:7 publications

Grant number: 1019945

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $27,867.48

  • Funder

    Decanato de Pesquisa e Inovação - Universidade de Brasilia (DPI)

  • Principal Investigator

    Unspecified Márcia Renata Mortari

  • Research Location

    Brazil

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

On January 28, 2020, the number of confirmed cases of SARS-Cov-2 in the world exceeded 600,000 and the number of deaths exceeded the 27,000,000 mark. The lethality rate of this virus in patients without any comorbidity is only 1.4% while it reaches 8.4% in hypertensive patients, according to research carried out by the WHO in China, a reality that urges research on the action of the virus in patients with systemic arterial hypertension. In addition, patients with cardiovascular diseases are the main population in a state of severe infection, comprising 23.4% of those infected with the need for a mechanical respirator. In addition, studies in progress around the world point to a possible association between the poor prognosis in hypertensive patients contaminated by COVID-19 and the previous use of ACEI and BRAS.

7 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

Contact exposure to environmentally relevant pesticide residues in beeswax may affect honey bees in a laboratory setting.

A new cage design to test pesticide impacts on honey bees via toxicant exposure through sucrose, pollen and beeswax simultaneously.

A Meta-Omics Approach Using eDNA and eRNA for the Assessment of Biotic Communities Associated With Royal Jelly Produced by the Western Honey Bee (Apis mellifera L.).

Evaluating the seasonal efficacy of commonly used chemical treatments on Varroa destructor (Mesostigmata: Varroidae) population resurgence in honey bee colonies.

Development of a multiplex real-time quantitative reverse-transcription polymerase chain reaction for the detection of four bee viruses.

Oxalic acid application method and treatment intervals for reduction of Varroa destructor (Mesostigmata: Varroidae) populations in Apis mellifera (Hymenoptera: Apidae) colonies.

Mitigating Nosema ceranae infection in western honey bee (Apis mellifera) workers using propolis collected from honey bee and stingless bee (Tetrigona apicalis) hives.